Welcome to our dedicated page for AGILE THERAPEUTICS news (Ticker: AGRX), a resource for investors and traders seeking the latest updates and insights on AGILE THERAPEUTICS stock.
Agile Therapeutics Inc. (AGRX) is an innovative women's healthcare company focused on developing non-daily contraceptive solutions through its proprietary transdermal technology. This page serves as the definitive source for verified news and official announcements related to product developments, regulatory milestones, and corporate updates.
Investors and healthcare professionals will find comprehensive coverage of Twirla® contraceptive patch updates, financial performance reports, and strategic partnership announcements. Our curated collection ensures timely access to earnings releases, clinical trial progress, and manufacturing updates while maintaining strict adherence to factual reporting standards.
Key information categories include FDA regulatory communications, research advancements in transdermal drug delivery, and market expansion initiatives. All content is rigorously verified to provide reliable insights into the company's position within the women's health sector.
For those monitoring AGRX's progress in contraceptive innovation, we recommend bookmarking this page and checking regularly for essential updates. Our commitment to neutral, accurate reporting makes this your trusted resource for understanding Agile Therapeutics' role in advancing patient-centric healthcare solutions.
Agile Therapeutics, Inc. (Nasdaq: AGRX) announced it has regained compliance with the Nasdaq minimum bid price requirement after a notification from the Nasdaq Listing Qualifications Department. The company's stock had been below the $1.00 threshold for over 30 days but has maintained a closing bid price of $1.00 or greater for the past 10 consecutive business days, from April 11 to April 24, 2023. However, the company still faces challenges as it received a deficiency letter regarding its stockholders' equity, which must meet a minimum of $2,500,000 for continued listing. Agile has until May 11, 2023, to submit a Compliance Plan to address this equity issue. Failure to comply may lead to further actions, including potential delisting.
Agile Therapeutics, Inc. (Nasdaq: AGRX) announced a 1-for-50 reverse stock split approved by its board of directors, effective April 10, 2023, to increase its stock price for compliance with Nasdaq listing requirements. Following the split, the outstanding shares will decrease from approximately 46.6 million to about 932,101 shares, with no fractional shares issued. Stockholders will receive cash for any fractional shares based on the last closing price. The change will also adjust the exercise prices of outstanding stock options and warrants. This decision aims to ensure Agile remains listed on Nasdaq despite previous price challenges.
Agile Therapeutics (Nasdaq: AGRX) reported a significant 33% increase in fourth quarter 2022 net revenue to $4.0 million, compared to $3.0 million in the third quarter. The company's operating expenses decreased by 55% to $9.2 million, contributing to a 165% overall revenue growth for 2022 at $10.9 million. Twirla demand surged by 25%, and factory sales rose by 31% in Q4 2022. Agile maintains its expected revenue guidance for 2023 in the $25-$30 million range, highlighting ongoing collaborations to expand its market reach. However, cash reserves dropped to $5.2 million from $19.1 million year-over-year.
FAQ
What is the current stock price of AGILE THERAPEUTICS (AGRX)?
What is the market cap of AGILE THERAPEUTICS (AGRX)?
